Please upgrade your browser.
Galena Biopharma (Nasdaq:GALE - News), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced the appointment of Robert Figlin, M.D., F.A.C.P. to the Company's Scientific Advisory Board (SAB). [Ed. note: Dr. Figlin is an adviser to the Kidney Cancer Association]
This tax is especially pernicious because it is assessed on sales, not profits. To put this in perspective, imagine that you've manufactured medical devices and had sales of $1 million, after all your costs and expenseseverything from materials and labor to research and developmentyour profit was $100,000. The excise tax would be $23,000, wiping out almost 25% of your profits.
CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine1949 to the presentto be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment optionsincluding new, promising, off-label and experimental.
The statistics do show an increase in rare cancers liver, thyroid and kidney, but that doesnt mean more people are dying from these cancers, said Luba Slatskova, a researcher with the society.
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
For males,there are a number of cancer sites which have an age-standardised incidence rate that is projected to increase at a rate of 1% or more per year.
A Beautifully illustrated paperback with more than 100 pages of information that could help to save your life or the life of someone you love. 2010 and 2011 editions are available free of charge. See our website for updates. Also available for the Kindle on www.Amazon.com.
Three drug companies and three prices on their respective versions of Sorafenib, a medicine used to treat advanced kidney cancer.
This is a Phase II study. Patients with kidney carcinoma will be considered in two groups.
Researchers had previously believed that only melanoma and kidney cancer had the right properties to respond to immune system therapy...
|Powered by NeonCRM|